Valuation: Arcellx, Inc.

Market Cap 6.75B 5.92B 5.47B 5.03B 9.49B 651B 9.64B 65.41B 25.64B 319B 25.35B 24.8B 1,098B P/E 2024
-38.3x
P/E 2025 -16x
Enterprise Value 6.28B 5.51B 5.09B 4.68B 8.83B 606B 8.98B 60.87B 23.86B 296B 23.59B 23.08B 1,021B EV / Sales 2024
33,125,319x
EV / Sales 2025 148,161,186x
Free-Float
88.44%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Arcellx, Inc.

1 day+0.03%
3 months+0.06%
6 months+59.44%
Current year+76.49%
Current year 60.36
Extreme 60.355
115.13
1 year 60.36
Extreme 60.355
115.13
3 years 30.88
Extreme 30.88
115.13
5 years 6.04
Extreme 6.035
115.13
10 years 6.04
Extreme 6.035
115.13
Date Insider Type Main position Quantity % Market Cap.
4/28/26 A Tender

Director

216,666 0.3705%
4/28/26 A Issuer sale

Director

18,613 0.0318%
4/28/26 A Tender

Chief Financial Officer

598,829 1.0240%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+70.25%+241.05% 6.75B
-0.49%-4.01%-0.84%+2.28% 49.18B
-3.10%-1.94%+370.99%+572.60% 39.58B
-0.46%+2.18%+5.44%+61.01% 34.69B
-1.14%-1.76%+26.94%-9.93% 34.42B
-1.82%-1.43%+0.52%+31.85% 27.11B
-3.54%-5.08% - - 16.21B
-1.82%-0.43%+69.28%+113.82% 15.36B
+1.17%+2.30%+15.87%+18.26% 14.05B
-2.25%+0.05%+15.77%-32.83% 13.02B
Average -1.34%-0.76%+63.80%+110.90% 25.04B
Weighted average by Cap. -1.40%-0.99%+75.75%+122.21%

Financials

2024 2025
Net sales 107.94 94.61 87.45 80.43 151.75 10.41K 154.19 1.05K 409.9 5.09K 405.3 396.46 17.55K 22.29 19.53 18.06 16.61 31.33 2.15K 31.84 215.9 84.63 1.05K 83.68 81.86 3.62K
Net income -107M -94.09M -86.97M -79.99M -151M -10.35B -153M -1.04B -408M -5.06B -403M -394M -17.45B -229M -201M -185M -171M -322M -22.08B -327M -2.22B -869M -10.8B -860M -841M -37.22B
Net Debt -572M -501M -463M -426M -804M -55.12B -816M -5.54B -2.17B -26.97B -2.15B -2.1B -92.91B -468M -410M -379M -349M -658M -45.14B -669M -4.54B -1.78B -22.09B -1.76B -1.72B -76.1B
Logo Arcellx, Inc.
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Employees
209
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ACLX Stock